Make An Appointment Make A Payment Event Registration
Make an appointment

Mark Fleisher, M.D.

Mark Fleisher, M.D.

Dr. Fleisher came to the Borland-Groover Clinic in 1998. Dr. Fleisher completed his medical training at Lenox Hill Hospital in New York City. Dr. Fleisher has published and presented at national meetings on new treatments in the management of inflammatory bowel disease. He is presently studying new treatment agents in the management of inflammatory bowel disease, and is an active speaker nationally in IBD. In addition, he started the first annual meeting for patients in the Jacksonville area suffering with IBD. Dr. Fleisher is the Director of the Borland-Groover Clinic Infusion Center.

Office locations

Baptist Downtown Office

Practicing since

1998

Certifications

  • American Board of Internal Medicine, Board Certified
  • American Board of Gastroenterology, Board Certified

Licensure

Florida

Communicate with your physician’s staff through My BGC Health.

Professional Clinical Positions

Professional Clinical Positions
1998 - Present Borland-Groover Clinic, P.A. Jacksonville, Florida
2006 – Present Director of Infusion Therapy Clinic, Borland-Groover Clinic Jacksonville, Florida
2006 – Present Director of IMID (Immune Mediated Inflammatory Diseases) Clinic, Borland – Groover Clinic Jacksonville, Florida

Medical Education

Medical Education
1986 – 1990 Doctor of Medicine Sackler School of Medicine, Tel Aviv University Tel Aviv, Israel

Postgraduate Education

Postgraduate Education
1994 - 1996 Gastroenterology Fellowship Lenox Hill Hospital New York, New York
1990 - 1994 Residency, Internal Medicine Lenox Hill Hospital New York, New York

Undergraduate Education

Undergraduate Education
1978 - 1982 Bachelor of Arts School of Arts and Sciences, New York University New York, New York

Professional Associations

  • Crohn’s and Colitis Foundation of America

Publications

Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P Ustekinumab Crohn’s Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008 Oct;135(4):1130-41

Warman JI, Korelitz BI, Fleisher MR, Janardhanam R. Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn’s disease and ulcerative colitis. J Clin Gastroenterol. 2003 Sep;37(3):220-5.

Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003 Aug;98(8):1821-6.

Fleisher MR, Rubin SD, Levine AE. The Myriad Manifestations of Crohn’s Disease Responsive to Infliximab. Therapeutic Options for Crohn’s and Colitis: A Case-Based Approach. 2001 November

Fleisher MR, Hopkins, K. Infliximab in the Treatment of Crohn’s Disease Complicated by Granuloma Annulare. Therapeutic Options for Crohn’s and Colitis: A Case-Based Approach. 2001 September

Korelitz BI, Mirsky FJ, Fleisher MR, Warman JI, Wisch N, Gleim GW. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol. 1999 Nov;94(11):3248-53.

Zlatanic J, Fleisher M, Sasson M, Kim P, Korelitz BI. Crohn’s disease and acute leukocytoclastic vasculitis of skin. Am J Gastroenterol. 1996 Nov;91(11):2410-3. Review.

Fleisher MR. Lending a hand. Nursing. 1994 Jul;24(7):32T

Fleisher MR. A piece of my mind. Hands on. JAMA. 1994 Mar 2;271(9):642.

Abstracts

A Multicenter, Randomized Phase 2a Study of Human Monoclonal Antibody to IL-12/23p40 (CNTO 1275) in Patients With Moderately to Severe Active Crohn’s Disease. Plenary Session, DDW 2007

Safety of Infliximab with Previously Treated Neoplasms. Poster Presentation, DDW 2003

Steroids Versus Infliximab: Efficacy and Swiftness of Induction to Remission. Poster Presentation, DDW 2003

Infliximab: Is it a 5-ASA and Antibiotics Sparing Drug in Crohn’s Disease? Poster Presentation, DDW 2003

Infliximab in the Treatment of IBD-Associated Psoriasis and Psoriasis-Associated IBD. Poster Presentation, ACG 2002

Collagenous Colitis: Experiences of a Large Community-Based Practice. Poster Presentation, ACG 2002

Successful Treatment of IBD-Associated Pyoderma Gangrenosum with Infliximab. Poster Presentation, DDW 2002

Antinuclear Antibody and Rheumatoid Factor Expression in IBD Patients During Severe Presentations. Poster Presentation, DDW 2002

Infliximab in the Treatment of Steroid Refractory Erythema Nodosum of IBD. Poster Presentation, DDW 2002

A Continuum of the Aspiration Technique in Biliary Type 3 Sphincter of Oddi Manometry Patients and the Incidence of Pancreatitis. Poster Presentation, DDW 2002

Infliximab in the Treatment of Crohn’s Disease Complicated by Granuloma Annulare. Poster Presentation, AAD National Conference 2001

REMICADEÒ (Infliximab) in the Management of Pyoderma Gangrenosum. Poster Presentation, AAD National Conference 2001

Infliximab in the Treatment of Steroid-Naïve Ulcerative Colitis. Poster Presentation, ACG National Conference 2001

Infliximab in the Treatment of Crohn’s Disease: Is It a Steroid Sparing Agent or a Steroid Replacing Agent? Poster Presentation, ACG National Conference 2001

A Case Report: Infliximab in the Treatment of Bechet’s Syndrome. Poster Presentation, ACG National Conference 2001

Remicade in the Treatment of Refractory Extraintestinal Manifestations of Crohn’s Disease. Poster Presentation, DDW 2001

Malignant Neoplasms Subsequent to Treatment of Inflammatory Bowel Disease with 6 – Mercaptopurine. Plenary Session Presentation ACG National Conference 1996

Intravenous ACTH versus Hydrocortisone in the Treatment of Hospitalized Patients with Crohn’s Disease. Plenary Session Presentation ACG National Conference 1995

Hypokalemia Due to Intravenous Hydrocortisone versus ACTH in the Treatment of Hospitalized Patients with Crohn’s Disease. Poster Presentation ACG National Conference 1995